InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1728328
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
InMed Pharma filed an 8-K on Sept 5th, check for material updates.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on September 8, 2025, reporting an event on September 5, 2025. The filing is a current report and includes financial statements and exhibits, as well as a Regulation FD Disclosure. The company is incorporated in British Columbia and its principal executive offices are located in Vancouver, Canada.
Why It Matters
This 8-K filing indicates a significant event or disclosure by InMed Pharmaceuticals Inc., requiring immediate reporting to the SEC and public investors.
Risk Assessment
Risk Level: low — This filing is a standard 8-K current report, not indicating any immediate negative events.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer of the 8-K report
- September 5, 2025 (date) — Earliest event date reported
- September 8, 2025 (date) — Filing date of the 8-K
- Vancouver, B.C. Canada (location) — Location of principal executive offices
FAQ
What specific event triggered this 8-K filing?
The filing does not specify the exact event, only that it is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, and includes Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on September 5, 2025.
What is the company's principal executive office location?
The company's principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada, V6C 3E8.
What is the company's SEC file number?
The SEC file number for InMed Pharmaceuticals Inc. is 001-39685.
What type of report is this 8-K filing?
This is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-09-05 19:25:38
Filing Documents
- ea0256293-8k_inmed.htm (8-K) — 41KB
- ea025629301ex99-1_inmed.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-25-085213.txt ( ) — 263KB
- inm-20250905.xsd (EX-101.SCH) — 3KB
- inm-20250905_def.xml (EX-101.DEF) — 26KB
- inm-20250905_lab.xml (EX-101.LAB) — 33KB
- inm-20250905_pre.xml (EX-101.PRE) — 22KB
- ea0256293-8k_inmed_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated September 5, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: September 5, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2